Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Herrstedt

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|February 23, 2012
Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortalityT L Jørgensen, J Hallas, S Friis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2016
MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline updateA Molassiotis, M Aapro, J Herrstedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapyT Sigsgaard, J Herrstedt, J Handberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)J Herrstedt, M S Aapro, F Roila, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 2, 2000
Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapyT Sigsgaard, J Herrstedt, P Christensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2014
Bone health in cancer patients: ESMO Clinical Practice GuidelinesR Coleman, J J Body, M Aapro, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Corticosteroids, dopamine antagonists and other drugsJ Herrstedt, M S Aapro, J F Smyth, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 12, 1998
Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapyJ Handberg, V Wessel, L Larsen, et al.
The New England Journal of Medicine|April 15, 1993
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapyJ Herrstedt, T Sigsgaard, M Boesgaard, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1989
The value of yearly chest X-ray in patients with stage I breast cancerA Vestergaard, J Herrstedt, H S Thomsen, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|February 23, 2012
Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortalityT L Jørgensen, J Hallas, S Friis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2016
MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline updateA Molassiotis, M Aapro, J Herrstedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapyT Sigsgaard, J Herrstedt, J Handberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)J Herrstedt, M S Aapro, F Roila, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 2, 2000
Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapyT Sigsgaard, J Herrstedt, P Christensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2014
Bone health in cancer patients: ESMO Clinical Practice GuidelinesR Coleman, J J Body, M Aapro, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Corticosteroids, dopamine antagonists and other drugsJ Herrstedt, M S Aapro, J F Smyth, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 12, 1998
Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapyJ Handberg, V Wessel, L Larsen, et al.
The New England Journal of Medicine|April 15, 1993
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapyJ Herrstedt, T Sigsgaard, M Boesgaard, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1989
The value of yearly chest X-ray in patients with stage I breast cancerA Vestergaard, J Herrstedt, H S Thomsen, et al.
Pageof 7